Clinical Trials Directory

Trials / Unknown

UnknownNCT03301961

Multiplex Analysis of Circulating Tumor DNA

The Clinical Applications of Multiplex Analysis of Circulating Tumor DNA Biomarkers in Lung Cancer Patients

Status
Unknown
Phase
Study type
Observational
Enrollment
400 (estimated)
Sponsor
Peking University People's Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

Lung cancer is the leading cause of cancer-related death in China. This study will explore the applications of multiplex analysis of circulating tumor DNA biomarkers for diagnosis and surveillance of lung cancer patients

Detailed description

Non-small cell lung cancer (NSCLC) constitutes about 85% of all newly diagnosed cases of lung cancer and continues to be the leading cause of cancer-related deaths worldwide.Early diagnosis and monitoring tumor recurrence after surgery are still far from satisfying. Circulating tumor DNA(ctDNA) detection has been proved to be feasible in early stage NSCLC in previous studies.Both genomic mutation and methylation a promising biomarker.Therefore,this study will perform multiplex detection of ctDNA,analysing mutations, methylation and other biomarkers,focusing on the early diagnosis and postoperative surveillance for NSCLC patients.

Conditions

Timeline

Start date
2019-04-11
Primary completion
2020-06-01
Completion
2022-06-01
First posted
2017-10-04
Last updated
2020-02-05

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03301961. Inclusion in this directory is not an endorsement.